RC
Recce Pharmaceuticals Ltd
RCE.AX · ASX
$0.37 +2.78% (+$0.01)
1M -6.49%
Market Cap $113.1M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.19
48.6% downside
Current Price
$0.37
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RCE.AX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
-
N/A PEG N/A
P/S N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
57 /100
Average ROA 175.44%
Asset turnover 0.00x
ROIC 238.75%
Debt
1 /100
High Int. coverage -13.96x
Current ratio 0.44x
Net debt/EBITDA N/A
Stability
28 /100
Unstable Rev. volatility 78.25%
EPS volatility 38.51%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RCE.AX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
James Hamilton-Bray Graham
Employees
8
Headquarters
Sydney
Upcoming events
01 MAR
Earnings
Upcoming earnings report